Intelligent Migraine Treatment System

A novel system integrating IoT, AI, blockchain, and novel materials to optimize migraine treatment with ubrogepant, enhancing patient outcomes and improving treatment efficacy.

The original patent disclosed methods for treating migraine with ubrogepant, but these methods lacked real-time monitoring, personalized dosing, and secure data tracking. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.

The system comprises a wearable IoT device monitoring physiological parameters, a blockchain-secured database storing said parameters, and a method for administering ubrogepant based on said parameters. AI-driven analysis of patient data and wearable sensor inputs optimizes ubrogepant dosing and administration timing. A mobile application utilizing machine learning algorithms predicts migraine onset, and a wearable device administers ubrogepant in response to said prediction. A blockchain-based ledger tracks ubrogepant administration, and an AI-driven analytics platform provides insights on treatment outcomes. A novel material-based transdermal patch enables efficient ubrogepant delivery.

The integration of IoT, AI, blockchain, and novel materials with ubrogepant treatment is new and non-obvious, providing a synergistic combination that enhances patient outcomes and improves treatment efficacy.

Alternative embodiments include using different machine learning algorithms, integrating additional sensors, or utilizing alternative blockchain platforms. Variations may include using different migraine treatments or expanding the system to treat other neurological conditions.

The Intelligent Migraine Treatment System has significant commercial potential in the pharmaceutical and healthcare industries, targeting patients and healthcare providers seeking more effective and personalized migraine treatments.